Physician profile
Avinash D Shah
NPI 1841269925
$13,744.33
in general payments reported to CMS, 2019-2025
55 companies · $1,270 in 2025
The $1,270 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,433 · 2020: $1,592 · 2021: $2,277 · 2022: $1,992 · 2023: $2,074 · 2024: $3,106 · 2025: $1,270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,461 · Travel and Lodging: $925 · Education: $64.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,460.73 |
| Travel and Lodging | $925.08 |
| Education | $64.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,952.28 | 2019-2025 | Krystexxa, Otezla, Repatha |
| Novo Nordisk INC | $1,873.73 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,787.43 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,323.92 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $906.83 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $855.27 | 2019-2025 | Jardiance, Synjardy |
| Pfizer INC. | $499.18 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $454.97 | 2019-2023 | Verquvo, Belsomra |
| Abbott Laboratories | $382.70 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $329.36 | 2019-2024 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $275.47 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $270.88 | 2019-2024 | |
| Eisai INC. | $259.17 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $218.13 | 2019-2024 | Xarelto |
| Vanda Pharmaceuticals INC. | $214.99 | 2020-2022 |
Show all 51 companies
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avinash Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.